Open Studies

Filter by eligibility
The AHEAD Study is the first research study that aims to help prevent Alzheimer’s disease by enrolling participants as young as 55 and using a tailored dosing approach.
The Wisconsin Alzheimer’s Disease Research Center (ADRC) and the Wisconsin Registry for Alzheimer’s Prevention (WRAP) at the University of Wisconsin-Madison are conducting a brain imaging research study to identify how Alzheimer’s disease develops. We use positron emission tomography (PET) to image amyloid plaques and neurofibrillary tangles.
The goal of the BRAVE study is to find out if a purified form of fish oil can stop or delay early brain changes associated with Alzheimer's disease in middle-aged, cognitively healthy Veterans at risk for this common form of dementia.
Help us learn why dementia affects Black Americans at higher rates than other groups.
The purpose of the Wisconsin Alzheimer's Disease Research Center (ADRC) Clinical Core is to help researchers identify people at risk for Alzheimer’s disease earlier and find better ways to prevent and treat Alzheimer’s disease and related memory disorders. People who join the Clinical Core attend either annual or every-other-year visits with a study partner and undergo memory and thinking abilities evaluations.
The Dementia Care Research Project is looking for people to participate in caregiving research studies. Dementia care research focuses on understanding how to improve the quality of life for people with memory concerns and their caregivers by examining the care they receive at home or within the healthcare system.
The KLOTHO study helps us further understand aging by looking at a gene, called KLOTHO, that may play a role in brain health.
This study will try to see if performing tongue press exercises and using a saliva substitute improve swallowing ability in patients with memory problems and dysphagia.
LUCINDA is a clinical research trial to determine whether leuprolide (Eligard, an injectable medication) can slow or prevent decline in thinking abilities and functioning in women with mild cognitive impairment (MCI) or Alzheimer’s disease who are also taking a cholinesterase inhibitor medication such as donepezil.
The MARS: Microbiome in Alzheimer’s Risk Study at the University of Wisconsin investigates the impact of human gut microbes on the development of Alzheimer’s disease. Differences between microbiomes discovered in this investigation would provide researchers with risk factors that can help diagnose and treat Alzheimer’s.
PREVENTABLE is a pragmatic evaluation of events and benefits of lipid-lowering in older adults. This is one of the largest research studies for older adults taking place at 100 locations across the country. The William S. Middleton Memorial Veterans’ Hospital is one of the PREVENTABLE sites looking to partner with people 75 years or older to learn if taking a statin could help older adults live well for longer by preventing dementia, disability, or heart disease. A statin is a commonly used drug to lower cholesterol. 
New studies start frequently at the Wisconsin ADRC, and we're looking for men and women volunteers. In order to match interested persons with future studies, the Wisconsin ADRC has created a research database — the Wisconsin ADRC Research Recruitment Registry — to hold the names and eligibility information of potential volunteers. When new studies become available, we will use the Wisconsin ADRC Registry to identify persons who may qualify for the new opportunity.
Dr. Megan Gilligan and The Families in Later Life Research Lab at Iowa State University are conducting a study to better understand the role of family dynamics in the health and well-being of adult children who provide care to a parent with Alzheimer’s disease or related dementia (ADRD).
The Synaptic Therapy Alzheimer’s Research Trial (START) is a national study funded by the National Institute on Aging (NIA) of the National Institutes of Health (NIH). Through the START study, researchers seek to learn if a new drug treatment taken orally, called CT1812, can safely slow memory loss caused by Alzheimer’s disease.
By our definition, SuperAgers are adults over age 80 who have the memory capacity of individuals who are at least three decades younger. Studying SuperAgers is important to understand what is going right with aging, as opposed to what is going wrong. The SuperAging program helps us identify those protective factors that contribute to remarkable memory performance in late life, including genetic, lifestyle and brain factors (such as what is found in the brain after death).